- Key Takeaways
- Illinois practices billing CountyCare must cross-reference every medical-benefit drug they administer against the updated HCPCS code list before the October 31, 2026 effective date.
- Specialty drug policy changes affect thirteen HCPCS-coded medications requiring new authorization, six additional NOC-billed drugs, and two medications, Depo-Provera and Kytril, dropped from the list.
- To submit a prior authorization request to CountyCare, you must use the provider portal for the fastest turnaround, since phone, fax, and email are slower.
- CountyCare’s new prior authorization requirements take effect October 31, 2026, following an August 28, 2026 provider notice that updated coverage under the HealthChoice Illinois medical benefit.
- Rising specialty drug costs and biosimilar approvals are driving CountyCare prior authorization changes, mirroring national trends where CMS now mandates seven-day standard decision turnarounds.
On August 28, 2026, CountyCare, the Medicaid managed care plan operated by Cook County Health, issued a provider notice updating prior authorization (PA) requirements for medications billed under the HealthChoice Illinois medical benefit. The changes take effect October 31, 2026, and touch thirteen drugs with assigned HCPCS codes, six additional drugs without codes yet assigned, and twelve underlying clinical policies.
If your practice bills CountyCare, or any Illinois Medicaid managed care plan, this is the kind of update that’s easy to miss until a claim comes back denied. Here’s what changed, what it means operationally, and why this particular notice is a useful case study in a much bigger problem: payer PA requirements that shift faster than most billing teams can track.
What CountyCare changed
CountyCare is one of five managed care organizations under HealthChoice Illinois, the state’s Medicaid managed care program, and the only one limited to Cook County. It’s currently the highest-rated Illinois Medicaid plan by NCQA standards, with a network of roughly 6,900 primary care providers and 29,750 specialists. Because of its size and its concentration in the Chicago market, PA policy changes at CountyCare have an outsized effect on Illinois RCM teams.
Medications that now require prior authorization
HCPCS code | Drug | Notes |
A9543 | Zevalin (ibritumomab tiuxetan) | Specialty Drug Management policy |
J1951 | Fensolvi (leuprolide acetate depot) | GnRH Products policy |
J3405 | Itvisma (onasemnogene abeparvovec-brve) | Gene therapy |
J7331 | SynoJoynt (hyaluronan derivative) | Intra-articular injection |
J8502 | Aponvie (aprepitant injection) | Medical Drug Step Therapy |
J9003 | Camcevi ETM (leuprolide injectable) | GnRH Products policy |
J9184 | Avgemsi (gemcitabine hydrochloride) |
|
J9282 | Zusduri (mitomycin) | Intravesical instillation |
J9326 | Emrelis (telisotuzumab vedotin-tllv) |
|
Q5160 | Jobevne (bevacizumab biosimilar) | Medical Drug Step Therapy |
Q5161 | Aukelso / Bosaya (denosumab-kyqq biosimilar) |
|
Q5162 | Bildyos / Bilprevda (denosumab-nxxp biosimilar) |
|
Q5164 | Starjemza (ustekinumab-hmny biosimilar) |
|
Six additional drugs, billed under not-otherwise-classified (NOC) codes, now also require PA: Avlayah (tividenofusp alfa-eknm), Kresladi (marnetegragene autotemcel), Loargys (pegzilarginase-nbln), Otarmeni (lunsotogene parvec-cwha), Yuviwel (navepegritide), and Zycubo (copper histidinate).
Medications where PA was removed
Two drugs move in the opposite direction, no longer requiring prior authorization:
HCPCS code | Drug |
J1050 | Depo-Provera (medroxyprogesterone acetate) |
Q0166 | Kytril (granisetron hydrochloride, oral) |
Twelve clinical policies also changed
Alongside the new drug list, CountyCare revised twelve clinical policies, including expanded indications for GnRH products, an ezetimibe prerequisite removed from the LEQVIO policy, an expanded age approval for ocrelizumab down to age 10 for relapsing-remitting MS, two new biosimilars added to the ustekinumab policy, and updated step-therapy codes across several biosimilars. Practices administering any of these therapies should pull the full policy language from CountyCare’s provider portal rather than relying on the code list alone, since criteria (not just the PA requirement itself) shifted in several cases.
- Neolytix • RCM
Revenue Cycle Management
Why this matters beyond CountyCare
CountyCare’s notice is a single, dated example of a pattern playing out across nearly every payer right now: prior authorization lists that turn over every few months, biosimilars entering the market and immediately picking up their own PA rules, and specialty drug management policies that get rewritten with little advance notice to billing teams.
The scale of the burden this creates is well documented. In its most recent survey, the American Medical Association found that 95% of physicians say prior authorization delays access to necessary care, and 79% report that patients abandon treatment altogether because of authorization hurdles. Physicians report completing an average of 40 prior authorization requests per week, consuming roughly 13 hours of combined physician and staff time, and 40% of practices now employ staff whose job is dedicated specifically to prior authorization. Nearly a third of physicians say requests are frequently or consistently denied.
Regulators are responding, but slowly. Under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), which applies to Medicaid managed care plans like CountyCare, payers were required as of January 1, 2026 to decide expedited PA requests within 72 hours and standard requests within seven calendar days, provide a specific reason for every denial, and publicly report PA metrics annually. Application programming interface requirements meant to make PA status and criteria easier to check electronically don’t take effect until January 1, 2027. Until then, the burden of tracking policy changes like CountyCare’s still falls largely on the provider side.
How practices should prepare
A few practical steps for any Illinois practice or billing team that bills CountyCare, or any payer that regularly updates its PA list:
- Audit your current authorization list against the new requirements. Cross-reference every drug your practice administers under the medical benefit against CountyCare’s updated code list before October 31, 2026. Don’t rely on memory or last quarter’s list.
- Pull the full clinical policy, not just the code. Several of CountyCare’s updated policies changed dosing criteria, age ranges, or prerequisite therapies, not just the PA requirement itself. A code-only review will miss those.
- Flag biosimilars specifically. Four of the thirteen newly restricted codes in this notice are biosimilars (Q-codes). As more biosimilars reach the market, expect this to be the fastest-moving category on most payers’ PA lists going forward.
- Build a standing process for payer bulletins, not a one-time check. CountyCare, like most Medicaid MCOs, issues these updates periodically throughout the year. A quarterly review cadence catches changes before they turn into denials.
- Know when to bring in outside authorization management. For practices juggling PA requirements across multiple payers, tracking every plan’s bulletin, code list, and clinical policy update in-house becomes its own full-time job, which is exactly why many practices choose to outsource prior authorization to a dedicated team.
How Neolytix helps
Neolytix’s prior authorization services exist for exactly this kind of payer volatility: our authorization specialists track payer-specific PA and medical necessity criteria (including Medicaid MCOs like CountyCare), submit and follow up on requests, and flag policy changes before they become denials on your claims. Combined with our broader revenue cycle management and denial management work, that means fewer surprises when a payer updates its authorization list mid-quarter. Neolytix has supported healthcare organizations for over 14 years, is ISO 27001 certified, and is HIPAA compliant, giving practices a governed, audit-ready partner for authorization management rather than another spreadsheet to maintain internally.
Conclusion
CountyCare’s October 2026 prior authorization changes are narrow on their own, thirteen drugs added, two removed, a dozen clinical policies updated. But they’re a useful snapshot of a much larger trend: payer PA requirements, especially for specialty and biosimilar drugs, are changing faster than most practices can track manually. Illinois providers billing CountyCare should audit their authorization lists now, ahead of the October 31 effective date, and build a repeatable process for catching the next update, because there will be a next one.
- Neolytix • Contact Us
Schedule a Consultation
Neolytix partners with healthcare organizations across revenue cycle, credentialing, and administrative operations ,14+ years of expertise and AI-enabled automation to reduce inefficiencies and drive sustainable growth.
Sources
- CountyCare Provider Notice: Prior Authorization Changes to Medications on Medical Benefit — CountyCare Health Plan, August 28, 2026
- AMA Survey: Prior Authorization Reform Pledge Falls Short with Physicians — American Medical Association, May 13, 2026
- CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) — Centers for Medicare & Medicaid Services
- HealthChoice Illinois Managed Care Program — Illinois Department of Healthcare and Family Services
- Cook County Health — background on CountyCare as the Cook County Health-operated Medicaid plan
Frequently Asked Questions
When do CountyCare's new prior authorization requirements take effect?
October 31, 2026. The notice was issued August 28, 2026, giving providers roughly two months to update their internal authorization workflows.
Which CountyCare drugs no longer require prior authorization?
Depo-Provera (medroxyprogesterone acetate, J1050) and oral Kytril (granisetron hydrochloride, Q0166) were removed from CountyCare’s PA list in this update.
Does this notice apply to pharmacy-benefit drugs too?
No. This update covers drugs billed under the HealthChoice Illinois medical benefit only, meaning drugs administered and billed by a provider (not filled at a pharmacy under the pharmacy benefit).
How do providers submit prior authorization requests to CountyCare?
CountyCare recommends the provider portal for the fastest turnaround. Requests can also go by phone (312-864-8200 or 855-444-1661, option 3), fax per the provider manual, or email at countycareproviderservices@cookcountyhhs.org.
Why are so many prior authorization changes tied to biosimilar drugs?
As biosimilars for drugs like bevacizumab, denosumab, and ustekinumab reach the market, payers add them to PA and step-therapy lists to manage cost and confirm appropriate use, since each biosimilar is technically a distinct product from its reference drug and often carries its own authorization criteria.
Do out-of-network providers need prior authorization from CountyCare?
Yes. Out-of-network requests go through Evolent Specialty Services (ESS) for review, and CountyCare redirects members to in-network providers where possible.
